• Scribe Therapeutics posted a Q2 net loss of USD 6.5 million, narrowing from USD 9.9 million a year earlier.
• Collaboration revenue fell 61.22% to USD 1.9 million on lower reimbursable R&D activity and reduced revenue recognition.
• R&D expense dropped 36.69% to USD 8.8 million on lower personnel and preclinical spending, partly offset by STX-1150 trial work.
• Cash, cash equivalents, and marketable securities were USD 43 million at June 30, 2026; net IPO and Sanofi placement proceeds were about USD 140.6 million.
• Initiated a Phase 1 trial of LDL-C therapy STX-1150; management said the period was “transformational,” with funding expected into H1 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-380184), on September 02, 2026, and is solely responsible for the information contained therein.